If you'd like to claim this profile on behalf of your company, please Contact Us.

Latest news ...

Some of our recent news articles.

11th January 2021

Sanofi to acquire Kymab for up to $1.45bn

PARIS and CAMBRIDGE, UK – January 11, 2021 – Sanofi and Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, have entered into an agreement under which Sanofi will acquire Kymab for an upfront payment of approximately $1.1 billion and up to $350 million upon achievement of certain milestones.

Read the full story »
25th February 2020

Sanofi to create massive standalone API producer by melding 6 sites in Europe; IPO to come

Paris - February 24, 2020 – Sanofi plans to create a major leading European company dedicated to the production and marketing to third parties of active pharmaceutical ingredients (API), which are the essential molecules responsible for the beneficial effects used in the composition of any drug. The project consists of creating a standalone company which would combine Sanofi’s API commercial and development activities with six of its European API production sites : Brindisi (Italy), Frankfurt Chemistry (Germany), Haverhill (UK), St Aubin les Elbeuf (France), Újpest (Hungary) and Vertolaye (France).

Read the full story »
04th November 2019

Sanofi confident for 2019 despite Q3 sales slip

Sales at the drugmaker’s vaccines unit down 9.8% over delay in WHO’s choice of flu inoculation

Read the full story »
10th May 2017

Sanofi vows to limit 2017 price hikes to 5.4% as part of new 'holistic' policy

Sanofi may be late to the pricing-pledge party, but it’s come up with some benchmarks that could have other drugmakers defending their own. Rather than limiting price hikes to less than 10%, the French drugmaker promises to keep any price increases at or below an official health inflation measure that’s projected to hit 5.4% in 2017.
Read the full story »
19th December 2016

Sanofi in talks to acquire biotech Actelion as J&J bows out

Swiss drugmaker Roche also touted as possible buyer for Europe’s largest biotech firm
Read the full story »
11th January 2016

Sanofi deepens cancer drive with $1.2 billion of deals, Innate jumps

Sanofi boosted its presence in cancer research on Monday by signing two deals with biotech companies worth up to $1.2 billion, as the French drugmaker plays catch-up with rivals in the hot research field.
Read the full story »
12th November 2015

Sanofi sees strong profit growth from 2018

Sanofi said on Friday investment in products to compensate for declining diabetes sales and cost cuts would prevent significant profit growth in the next two years.
Earnings per share will, however, grow faster than sales at constant exchange rates from 2018, by which time it plans to have taken out some €1.5 billion of costs, the French drugmaker said. Sanofi also said ahead of a presentation of its five-year strategic plan to investors in Paris it would raise annual research and development spending to €6 billion at constant exchange rates by 2020.
Read the full story »
20th February 2015

Sanofi names Olivier Brandicourt as chief executive

French drugmaker Sanofi has named Olivier Brandicourt, a Paris-educated doctor and head of Bayer’s healthcare arm, as its chief executive officer.

Mr Brandicourt had been widely tipped to become Sanofi’s new boss, a position that opened when Chris Viehbacher was suddenly sacked last year.

The 59-year-old Frenchman, who researched tropical and infectious diseases before joining the corporate pharmaceutical world, will take over as chief executive on April 2
Read the full story »

About Us

SURIMS is the new name for Actex Pharma Services which was a consultancy established in 2003, supporting companies in the identification, qualification and management of quality vendors and suppliers in ingredients and formulations.

The Pharmaceutical Services Directory supports the identification and on-boarding of quality suppliers and also incorporates software features that manage relationships between suppliers and their customers. These include the building and deployment of questionnaires and assessments, electronic signatures and sign-offs and project management between vendor/partner and customer.

Access to the features and software is available on a 'pay as you go' basis, or a customised version can be licensed for your company for its own supplier on-boarding and supplier management activities. Further information on our software services please contact Tel: +353 87 294 0436 or email info@surims.com


Get in Touch

The Pharmaceutical Services Directory


© 2021 Surims Ltd | All Rights Reserved.